EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Ceramide-Driven Mechanisms in Pulmonary Fibrosis

Zifan Li, Yaqian Li, Na Mao, Xuemin Gao, Hong Xu iD, Wenchen Cai, Tian Li

Metabolites · 16.06.2026 · 16 (6) · 421

DOI: 10.3390/metabo16060421 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 16.06.2026. Verfasst von Zifan Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, North China University of Science and Technology, Tangshan 063000, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Natural Science Foundation of Hebei Province, Hebei Provincial Department of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), is a chronic and progressive interstitial lung disease characterized by alveolar epithelial injury, fibroblast activation, and excessive extracellular matrix deposition, which collectively lead to respiratory failure. Despite the availability of antifibrotic agents, disease-modifying therapies remain limited. Emerging evidence has identified dysregulated sphingolipid metabolism, especially ceramide accumulation, as a key driver of fibrotic pathogenesis. Ceramide is a central bioactive lipid in the sphingolipid pathway that regulates multiple cellular processes, including apoptosis, inflammation, endothelial barrier dysfunction, and fibroblast activation, all of which contribute to pulmonary fibrosis. This review is a narrative review that systematically summarizes the biosynthetic and metabolic pathways of ceramide, with an emphasis on chain length-specific functions and the ceramide to S1P rheostat. We further discuss the mechanistic roles of ceramide in alveolar epithelial cell apoptosis, inflammatory responses, and vascular barrier disruption in fibrotic lung disease. Finally, we highlight emerging therapeutic strategies that target ceramide metabolism, including inhibitors of acid sphingomyelinase (ASMase) and serine palmitoyltransferase (SPT), and propose future directions for clinical translation.

Schlagwörter

Stichwörter der Autor:innen

acid sphingomyelinaseceramidefibroblast activationpulmonary fibrosissphingolipid

Autor:innen und Institutionen

  • School of Public Health, North China University of Science and Technology, Tangshan 063000, China.
  • School of Traditional Chinese Medicine, North China University of Science and Technology, Tangshan 063000, China.
  • Health Science Center, North China University of Science and Technology, Tangshan 063000, China.
  • Hebei Key Laboratory of Rehabilitation Engineering and Regenerative Medicine, College of Nursing and Rehabilitation, North China University of Science and Technology, Tangshan 063000, China.

ORCID-Profile: Hong Xu

Förderung

  • National Natural Science Foundation of China
  • National Natural Science Foundation of Hebei Province
  • Hebei Provincial Department of Education
  • Science and Technology Project of Tangshan
  • Provincial University Basic Research Fund
  • Hebei Education Department

Zitieren

APA

Li, Z., Li, Y., Mao, N., Gao, X., Xu, H., Cai, W., & Li, T. (2026). Ceramide-Driven Mechanisms in Pulmonary Fibrosis. Metabolites, 16(6), 421. https://doi.org/10.3390/metabo16060421

Vancouver

Li Z, Li Y, Mao N, Gao X, Xu H, Cai W, et al. Ceramide-Driven Mechanisms in Pulmonary Fibrosis. Metabolites. 2026;16(6):421. doi:10.3390/metabo16060421

BibTeX
@article{Li2026,
  author = {Li, Zifan and Li, Yaqian and Mao, Na and Gao, Xuemin and Xu, Hong and Cai, Wenchen and Li, Tian},
  title = {Ceramide-Driven Mechanisms in Pulmonary Fibrosis},
  journal = {Metabolites},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {421},
  doi = {10.3390/metabo16060421}
}
Kostenlos starten →